Bernelot Moens Sophie J, Verweij Simone L, van der Valk Fleur M, van Capelleveen Julian C, Kroon Jeffrey, Versloot Miranda, Verberne Hein J, Marquering Henk A, Duivenvoorden Raphaël, Vogt Liffert, Stroes Erik S G
Departments of *Vascular Medicine.
Experimental Vascular Medicine.
J Am Soc Nephrol. 2017 Apr;28(4):1278-1285. doi: 10.1681/ASN.2016030317. Epub 2016 Oct 31.
CKD associates with a 1.5- to 3.5-fold increased risk for cardiovascular disease. Both diseases are characterized by increased inflammation, and in patients with CKD, elevated C-reactive protein level predicts cardiovascular risk. In addition to systemic inflammation, local arterial inflammation, driven by monocyte-derived macrophages, predicts future cardiovascular events in the general population. We hypothesized that subjects with CKD have increased arterial and cellular inflammation, reflected by F-fluorodeoxyglucose (F-FDG) positron emission tomography computed tomography (PET/CT) of the arterial wall and a migratory phenotype of monocytes. We assessed F-FDG uptake in the arterial wall in 14 patients with CKD (mean±SD age: 59±5 years, mean±SD eGFR: 37±12 ml/min per 1.73 m) but without cardiovascular diseases, diabetes, or inflammatory conditions and in 14 control subjects (mean age: 60±11 years, mean eGFR: 86±16 ml/min per 1.73 m). Compared with controls, patients with CKD showed increased arterial inflammation, quantified as target-to-background ratio (TBR) in the aorta (TBR: CKD, 3.14±0.70 versus control, 2.12±0.27; =0.001) and the carotid arteries (TBR: CKD, 2.45±0.65 versus control, 1.66±0.27; <0.001). Characterization of circulating monocytes using flow cytometry revealed increased chemokine receptor expression and enhanced transendothelial migration capacity in patients with CKD compared with controls. In conclusion, this increased arterial wall inflammation, observed in patients with CKD but without overt atherosclerotic disease and with few traditional risk factors, may contribute to the increased cardiovascular risk associated with CKD. The concomitant elevation of monocyte activity may provide novel therapeutic targets for attenuating this inflammation and thereby preventing CKD-associated cardiovascular disease.
慢性肾脏病(CKD)与心血管疾病风险增加1.5至3.5倍相关。这两种疾病都具有炎症增加的特征,在CKD患者中,C反应蛋白水平升高可预测心血管风险。除了全身炎症外,由单核细胞衍生的巨噬细胞驱动的局部动脉炎症可预测普通人群未来的心血管事件。我们假设CKD患者的动脉和细胞炎症增加,这可通过动脉壁的F-氟脱氧葡萄糖(F-FDG)正电子发射断层扫描计算机断层扫描(PET/CT)以及单核细胞的迁移表型反映出来。我们评估了14例无心血管疾病、糖尿病或炎症性疾病的CKD患者(平均±标准差年龄:59±5岁,平均±标准差估算肾小球滤过率[eGFR]:37±12 ml/(min·1.73 m²))和14例对照受试者(平均年龄:60±11岁,平均eGFR:86±16 ml/(min·1.73 m²))动脉壁的F-FDG摄取情况。与对照组相比,CKD患者的动脉炎症增加,以主动脉的靶本底比值(TBR)量化(TBR:CKD组为3.14±0.70,对照组为2.12±0.27;P = 0.001),颈动脉的TBR也如此(TBR:CKD组为2.45±0.65,对照组为1.66±0.27;P<0.001)。通过流式细胞术对循环单核细胞进行表征发现,与对照组相比,CKD患者趋化因子受体表达增加,跨内皮迁移能力增强。总之,在无明显动脉粥样硬化疾病且传统危险因素较少的CKD患者中观察到的这种动脉壁炎症增加,可能导致与CKD相关的心血管风险增加。单核细胞活性的同时升高可能为减轻这种炎症从而预防CKD相关心血管疾病提供新的治疗靶点。